VIDI "Ellison Targets Additional Phase 3 Trials for Pancreatic Cancer Treatment in European and Asian Markets"

[Asia Economy Reporter Hyunseok Yoo] VIDI announced on the 22nd that its US subsidiary, Ellison Pharmaceuticals (Ellison), plans to conduct additional Phase 3 clinical trials targeting the European and Asian markets for the pancreatic cancer second-line treatment drug "Glufosfamide" currently under development.

The detailed clinical plan will be discussed in early November during a visit to the US, where meetings with Ellison CEO Edwin Thomas and CFO Keith Terra are scheduled. They will also discuss the current status and issues of the major ongoing pipeline clinical trials.

Ellison is conducting Phase 3 clinical trials of the pancreatic cancer second-line treatment drug "Glufosfamide" in the US. So far, the clinical trials are progressing smoothly with 480 patients enrolled. The brain cancer treatment drug "DBD" has demonstrated efficacy in both solid tumors and hematologic cancers, with plans to enter Phase 3 clinical trials by mid-next year.

The lung cancer treatment drug "ILC" is also progressing smoothly through Phase 2 clinical trials. A prototype treatment is expected to be prepared by the end of this year, with plans to complete Phase 2 trials next year. ILC has been designated as an orphan drug in the US and Europe, which is expected to significantly reduce both development costs and timelines.

Edwin Thomas, CEO of Ellison, stated, "We plan to introduce the excellence of Ellison's pipeline to investors through participation in the 'JP Morgan Conference 2022' and 'ASCO GI Symposium 2022' in January next year." He added, "In addition, we will meet with clinical managers and stakeholders for each major pipeline to share information and discuss ways to expedite clinical trials."

A VIDI official said, "Through this US visit, we plan to review the overall clinical trials of Ellison's major pipelines and conduct detailed discussions regarding additional clinical trials." He added, "We expect Ellison to present a more specific development roadmap for each pipeline during this meeting."